Existing studies have documented variations in BRCA1 and BRCA2 among early-onset CRC (1.3%), high-risk CRC (0.2%), and a general cohort of CRC patients (1.0%) at a relatively higher frequency. This evidence concerns the gene BRCA2 and colorectal carcinoma.